Medivation 8-K Other Events

1

Enzalutamide Prolonged Radiographic

Progression-Free Survival

Enzalutamide

832

Placebo

801

514

305

256

79

128

20

34

5

5

0

1

0

0

0

Time from Randomization (Months)

0

3

6

9

12

15

18

21

60

50

40

30

20

10

0

90

80

70

100

Enzalutamide

Placebo

Patients at Risk

Estimated median rPFS, months (95% CI):  Enzalutamide: NYR (13.8, NYR); Placebo: 3.9 (3.7, 5.4)

NYR = Not Yet Reached

Exhibit 99.2

Enzalutamide Reduced Risk of Death by 29%

2

Estimated median OS, months (95% CI):  Enzalutamide: 32.4 (30.1,

NYR); Placebo:  30.2 (28.0, NYR)

NYR = Not Yet Reached

Enzalutamide

872

Placebo

845

863

835

850

781

824

744

797

701

745

644

566

484

395

328

244

213

128

102

33

27

2

2

0

0

Duration of Overall Survival (Months)

60

50

40

30

20

10

0

90

80

70

100

0

3

6

9

12

15

18

21

24

27

30

33

36

Enzalutamide

Placebo

Patients at Risk

Patients still alive at data cut off

Enzalutamide:  72%; Placebo:  63%

Enzalutamide Delayed Median Time to

Chemotherapy by 17 Months

Enzalutamide

872

Placebo

845

854

734

799

518

751

415

665

324

575

257

388

165

252

103

158

64

78

25

21

9

2

0

0

0

Time to Initiation of Cytotoxic Chemotherapy (Months)

60

50

40

30

20

10

0

90

80

70

100

0

3

6

9

12

15

18

21

24

27

30

33

36

Median

Enzalutamide

28.0 months

Placebo

10.8 months

Enzalutamide

Placebo

3

Patients at Risk